Recombinant expression of Streptococcus pneumoniae capsular polysaccharides in Escherichia coli

Currently, Streptococcus pneumoniae is responsible for over 14 million cases of pneumonia worldwide annually, and over 1 million deaths, the majority of them children. The major determinant for pathogenesis is a polysaccharide capsule that is variable and is used to distinguish strains based on thei...

Full description

Bibliographic Details
Main Authors: Emily J. Kay, Laura E. Yates, Vanessa S. Terra, Jon Cuccui, Brendan W. Wren
Format: Article
Language:English
Published: The Royal Society 2016-01-01
Series:Open Biology
Subjects:
Online Access:https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.150243
_version_ 1818605813934063616
author Emily J. Kay
Laura E. Yates
Vanessa S. Terra
Jon Cuccui
Brendan W. Wren
author_facet Emily J. Kay
Laura E. Yates
Vanessa S. Terra
Jon Cuccui
Brendan W. Wren
author_sort Emily J. Kay
collection DOAJ
description Currently, Streptococcus pneumoniae is responsible for over 14 million cases of pneumonia worldwide annually, and over 1 million deaths, the majority of them children. The major determinant for pathogenesis is a polysaccharide capsule that is variable and is used to distinguish strains based on their serotype. The capsule forms the basis of the pneumococcal polysaccharide vaccine (PPV23) that contains purified capsular polysaccharide from 23 serotypes, and the pneumococcal conjugate vaccine (PCV13), containing 13 common serotypes conjugated to CRM197 (mutant diphtheria toxin). Purified capsule from S. pneumoniae is required for pneumococcal conjugate vaccine production, and costs can be prohibitively high, limiting accessibility of the vaccine in low-income countries. In this study, we demonstrate the recombinant expression of the capsule-encoding locus from four different serotypes of S. pneumoniae within Escherichia coli. Furthermore, we attempt to identify the minimum set of genes necessary to reliably and efficiently express these capsules heterologously. These E. coli strains could be used to produce a supply of S. pneumoniae serotype-specific capsules without the need to culture pathogenic bacteria. Additionally, these strains could be applied to synthetic glycobiological applications: recombinant vaccine production using E. coli outer membrane vesicles or coupling to proteins using protein glycan coupling technology.
first_indexed 2024-12-16T14:00:56Z
format Article
id doaj.art-826a99e70e3941628ce2e3f051f50a1b
institution Directory Open Access Journal
issn 2046-2441
language English
last_indexed 2024-12-16T14:00:56Z
publishDate 2016-01-01
publisher The Royal Society
record_format Article
series Open Biology
spelling doaj.art-826a99e70e3941628ce2e3f051f50a1b2022-12-21T22:29:06ZengThe Royal SocietyOpen Biology2046-24412016-01-016410.1098/rsob.150243150243Recombinant expression of Streptococcus pneumoniae capsular polysaccharides in Escherichia coliEmily J. KayLaura E. YatesVanessa S. TerraJon CuccuiBrendan W. WrenCurrently, Streptococcus pneumoniae is responsible for over 14 million cases of pneumonia worldwide annually, and over 1 million deaths, the majority of them children. The major determinant for pathogenesis is a polysaccharide capsule that is variable and is used to distinguish strains based on their serotype. The capsule forms the basis of the pneumococcal polysaccharide vaccine (PPV23) that contains purified capsular polysaccharide from 23 serotypes, and the pneumococcal conjugate vaccine (PCV13), containing 13 common serotypes conjugated to CRM197 (mutant diphtheria toxin). Purified capsule from S. pneumoniae is required for pneumococcal conjugate vaccine production, and costs can be prohibitively high, limiting accessibility of the vaccine in low-income countries. In this study, we demonstrate the recombinant expression of the capsule-encoding locus from four different serotypes of S. pneumoniae within Escherichia coli. Furthermore, we attempt to identify the minimum set of genes necessary to reliably and efficiently express these capsules heterologously. These E. coli strains could be used to produce a supply of S. pneumoniae serotype-specific capsules without the need to culture pathogenic bacteria. Additionally, these strains could be applied to synthetic glycobiological applications: recombinant vaccine production using E. coli outer membrane vesicles or coupling to proteins using protein glycan coupling technology.https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.150243streptococcus pneumoniaesynthetic glycobiologyglycoengineeringvaccinecapsular polysaccharide
spellingShingle Emily J. Kay
Laura E. Yates
Vanessa S. Terra
Jon Cuccui
Brendan W. Wren
Recombinant expression of Streptococcus pneumoniae capsular polysaccharides in Escherichia coli
Open Biology
streptococcus pneumoniae
synthetic glycobiology
glycoengineering
vaccine
capsular polysaccharide
title Recombinant expression of Streptococcus pneumoniae capsular polysaccharides in Escherichia coli
title_full Recombinant expression of Streptococcus pneumoniae capsular polysaccharides in Escherichia coli
title_fullStr Recombinant expression of Streptococcus pneumoniae capsular polysaccharides in Escherichia coli
title_full_unstemmed Recombinant expression of Streptococcus pneumoniae capsular polysaccharides in Escherichia coli
title_short Recombinant expression of Streptococcus pneumoniae capsular polysaccharides in Escherichia coli
title_sort recombinant expression of streptococcus pneumoniae capsular polysaccharides in escherichia coli
topic streptococcus pneumoniae
synthetic glycobiology
glycoengineering
vaccine
capsular polysaccharide
url https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.150243
work_keys_str_mv AT emilyjkay recombinantexpressionofstreptococcuspneumoniaecapsularpolysaccharidesinescherichiacoli
AT lauraeyates recombinantexpressionofstreptococcuspneumoniaecapsularpolysaccharidesinescherichiacoli
AT vanessasterra recombinantexpressionofstreptococcuspneumoniaecapsularpolysaccharidesinescherichiacoli
AT joncuccui recombinantexpressionofstreptococcuspneumoniaecapsularpolysaccharidesinescherichiacoli
AT brendanwwren recombinantexpressionofstreptococcuspneumoniaecapsularpolysaccharidesinescherichiacoli